Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 3, 2025

Phospho-MEK1/2 (Ser217/221) (41G9) Rabbit mAb

RRID:AB_2138017
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 9154, RRID:AB_2138017)

Antibody Information

URL: http://antibodyregistry.org/AB_2138017

Proper Citation: (Cell Signaling Technology Cat# 9154, RRID:AB_2138017)

Target Antigen: Phospho-MEK1/2 (Ser217/221)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP
Consolidation: AB_10171691.

Antibody Name: Phospho-MEK1/2 (Ser217/221) (41G9) Rabbit mAb

Description: This monoclonal targets Phospho-MEK1/2 (Ser217/221)

Target Organism: Human, Rat, Monkey, Mouse

Clone ID: 41G9

Antibody ID: AB_2138017

Vendor: Cell Signaling Technology

Catalog Number: 9154

Alternative Catalog Numbers: 9154P, 9154S

Record Creation Time: 20231110T080225+0000

Record Last Update: 20241115T030737+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-MEK1/2 (Ser217/221) (41G9) Rabbit mAb.

No alerts have been found for Phospho-MEK1/2 (Ser217/221) (41G9) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 86 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Wu Q, et al. (2024) Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(1), 198.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy, 25(1), 2332000.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer research communications, 4(2), 337.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO reports, 25(9), 3944.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. Research square.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Mastrototaro G, et al. (2023) Ablation of palladin in adult heart causes dilated cardiomyopathy associated with intercalated disc abnormalities. eLife, 12.

Fan F, et al. (2023) Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PloS one, 18(3), e0281063.

Bortolami A, et al. (2023) Integrin-KCNB1 potassium channel complexes regulate neocortical neuronal development and are implicated in epilepsy. Cell death and differentiation, 30(3), 687.

Martín-Vega A, et al. (2023) Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. Science advances, 9(7), eadd7969.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. Cell reports, 42(1), 112031.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell reports. Medicine, 4(11), 101244.

Chen L, et al. (2023) KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2. iScience, 26(6), 106914.

Wang Y, et al. (2023) Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell death discovery, 9(1), 60.

Tomas Bort E, et al. (2023) Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. eLife, 12.

de Miguel FJ, et al. (2023) Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer cell, 41(8), 1516.

Xu X, et al. (2023) Sox10 escalates vascular inflammation by mediating vascular smooth muscle cell transdifferentiation and pyroptosis in neointimal hyperplasia. Cell reports, 42(8), 112869.

Wong S, et al. (2023) RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis. EMBO molecular medicine, 15(5), e17078.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. European journal of pharmacology, 961, 176157.

Hondo N, et al. (2023) MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer letters, 567, 216264.